KRAS and cancer: Imamura et al., in a study involving 1075 BRAF wild-type cancers, reported that patients harboring KRAS codon 12 mutations exhibited significantly higher colorectal-cancer-specific mortality compared with those with KRAS wild-type/BRAF wild-type tumors.